Enhancing Diagnostic Accuracy for Lung Cancer through Combined Detection of Multiple Tumor Markers.

Objective: To explore the application value of combined detection of multiple tumor markers in diagnosing lung cancer (LC). Methods: A total of 32 small cell lung cancer (SCLC) patients and 107 non-small cell lung cancer (NSCLC) patients, including 68 lung adenocarcinoma (LADC) patients and 39 lung squamous cell carcinoma (LSCC) patients diagnosed in our hospital from January 2019 to December 2021, were enrolled. 102 benign lung disease (BCD) patients (including pneumonia, pulmonary tuberculosis, and chronic obstructive pulmonary disease) were chosen as the control group. Serum tumor markers were detected in all patients, and their positive rates and concentrations were compared. Receiver operating characteristic (ROC) curve analysis was used to calculate the diagnostic performance of individual and combined tests. Results: The positive rate and concentration of carcinoembryonic antigen (CEA) were upregulated in the LADC group (P < .05). The positive rate and concentration of squamous cell carcinoma antigen (SCCAg) were upregulated in the LSCC group (P < .05). The positive rate and concentration of carbohydrate antigen 153 (CA153) were upregulated in the SCLC group (P < .05). The positive rate and concentration of cytokeratin fragment antigen 21-1 (CYFRA21-1) were the highest in the LADC and LSCC groups. The ROC curve demonstrated that CEA exhibited higher diagnostic sensitivity and specificity in LADC patients, SCCAg exhibited higher diagnostic sensitivity and specificity in LSCC patients, and CYFRA21-1 exhibited the highest diagnostic sensitivity in LADC and LSCC patients. In combined detection, the 4-marker combined detection and single-marker combined detection showed statistical significance in patients with different pathological types of LC (P < 0.05). Conclusions: CYFRA21-1 combined with CEA assists in diagnosing LADC, CYFRA21-1 combined with SCCAg assists in diagnosing LSCC, and CA153 assists in diagnosing SCLC. These four serum tumor markers can be used to aid in diagnosing LC and differentiating its pathological types.